VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.
The POC testing market is set to reach $49 billion by 2018.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $49 billion by 2018.

Patents applications that have recently evolved from our internal research program include:

  1. Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation.
  2. New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation.
  3. Microcirculation and vascular characteristics.
  4. Prevention and counteraction of diet-induced thrombosis risk.
  5. Epidermal skin health.

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com